NASDAQ$COGT
Cogent Biosciences Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Cogent Biosciences reported Q3 2025, a net loss of $80.9M.
For Q3 2025, Cogent Biosciences reported a net loss of $80.9M. Management discusses operating trends, liquidity, and priorities as disclosed in the filing.
- Net loss $80.9M.
- Cogent Biosciences updated strategic and capital priorities in the filing.
- Cogent Biosciences updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Cogent Biosciences · Revenue · Quarterly
$0
Forward guidance
The filing discusses Cogent Biosciences's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Cogent Biosciences cites execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+0.9%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+4.5%
Avg return
30 days after
65%
20 / 31 earnings
Positive
+17.8%
Q3 2018
Best reaction
-24.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -5.3% | -10.6% | |
| Q3 2025 | -4.4% | -9.1% | +140.2% | |
| Q2 2025 | -5.8% | -9.0% | +7.4% | |
| Q1 2025 | +2.7% | +4.4% | +48.4% | |
| Q4 2024 | -6.3% | +0.9% | -11.4% | |
| Q3 2024 | +0.0% | -14.4% | -19.8% | |
| Q1 2024 | +0.4% | -0.1% | +11.1% | |
| Q4 2023 | +0.7% | -2.8% | -12.4% | |
| Q3 2023 | +3.9% | +3.8% | -2.7% | |
| Q2 2023 | +7.3% | +8.8% | +9.4% | |
| Q1 2023 | -1.5% | -2.6% | -2.9% | |
| Q4 2022 | +0.7% | -5.1% | -13.7% | |
| Q3 2022 | -5.7% | -8.5% | -2.6% | |
| Q2 2022 | +9.6% | +12.1% | +32.7% | |
| Q1 2022 | -24.0% | -26.8% | -10.6% | |
| Q4 2021 | +4.5% | +28.4% | +64.6% | |
| Q3 2021 | +13.7% | +12.1% | -9.9% | |
| Q2 2021 | +5.4% | +13.4% | +3.3% | |
| Q1 2021 | +1.7% | +4.9% | +4.0% | |
| Q4 2020 | +5.9% | +5.5% | +9.0% | |
| Q3 2020 | +13.2% | +9.8% | +14.9% | |
| Q2 2020 | -11.4% | -11.0% | -8.3% | |
| Q1 2020 | +0.5% | +17.9% | +37.1% | |
| Q4 2019 | -3.1% | -15.5% | -18.6% | |
| Q3 2019 | -10.2% | -32.6% | -52.1% | |
| Q2 2019 | +4.4% | +9.3% | +9.0% | |
| Q1 2019 | +0.2% | -1.1% | -26.2% | |
| Q4 2018 | +8.1% | +5.4% | -12.3% | |
| Q3 2018 | +17.8% | +18.5% | -25.0% | |
| Q2 2018 | -5.9% | -12.8% | -27.3% | |
| Q1 2018 | +4.0% | +12.4% | +13.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro